2021-06-24| ChinaR&D

China’s Legend Biotech to Build a CAR-T Therapy Production Site in Belgium

by Tyler Chen
Share To

Fresh off completing a rolling submission for ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy co-developed with Janssen, China’s Legend Biotech, has announced plans to establish a manufacturing facility in Belgium to boost the production of cilta-cel once it’s FDA approved.


Third Plant for Legend Biotech, a First in Europe

The Belgium facility is going to be the first plant in Europe and the third for Legend Biotech on top of the two in Nanjing, China, and New Jersey, US. For now, details of the plant remain unclear, but the site is expected to go into operation by 2023 and focus on manufacturing cell therapy products.

Also, it would put Legend Biotech in a better position to tap the local talent pool and support global supply as soon as cilta-cel gets approved.


Collaboration with Janssen

Janssen started working with Legend Biotech on developing CAR-T therapy at the end of 2017. The drug is developed for patients with relapsed/refractory multiple myeloma. It received a Breakthrough Therapy Designation (BTD) in the US in December 2019 and also got priority review in May 2021, meaning the FDA will make the decision by November 29th. What’s more, it’s the first CAR-T therapy accepted for review by the China Food and Drug Administration (CFDA).


Approved CAR-T Therapies

If approved, cilta-cel will be the second CAR-T therapy to treat those with relapsed/refractory multiple myeloma as BMS and bluebird bio won the race in March with Abecma, entering the market as the fifth CAR-T therapy and the first for the indication.

Currently, the US FDA has approved five CAR-T therapies, including Abecma and Breyanzi by BMS, Tecartus and Yescarta by Gilead, and Kymriah by Novartis.

Related Article: From Great Challenges to Great Opportunities: An Outlook on US-China Biotech Relationships


© All rights reserved. Collaborate with us:
Related Post
Mesoblast’s Resubmission Brings First-of-its-Kind Therapy One Step Closer to Approval
Exciting Cell & Gene Therapy Research Updates in Glaucoma and Nerve Regeneration
Developments in Regenerative Medicine: Gene Delivery Tools and Cell Therapy for Parkinson’s Disease
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top